Recent advances in delivery of drug-nucleic acid combinations for cancer treatment

JOURNAL OF CONTROLLED RELEASE

卷:172

Review

Oupicky, David¹ 

[1] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA

关键词: Gene delivery;    Cancer treatment;    Drug delivery;    Combination therapy;    Multifunctional nanocarriers;    siRNA delivery;   

DOI  :  10.1016/j.jconrel.2013.04.010

来源: Elsevier

【 摘 要 】

Cancer treatment that uses a combination of approaches with the ability to affect multiple disease pathways has been proven highly effective in the treatment of many cancers. Combination therapy can include multiple chemotherapeutics or combinations of chemotherapeutics with other treatment modalities like surgery or radiation. However, despite the widespread clinical use of combination therapies, relatively little attention has been given to the potential of modern nanocarrier delivery methods, like liposomes, micelles, and nanoparticles, to enhance the efficacy of combination treatments. This lack of knowledge is particularly notable in the limited success of vectors for the delivery of combinations of nucleic acids with traditional small molecule drugs. The delivery of drug-nucleic acid combinations is particularly challenging due to differences in the physicochemical properties of the two types of agents. This review discusses recent advances in the development of delivery methods using combinations of small molecule drugs and nucleic acid therapeutics to treat cancer. This review primarily focuses on the rationale used for selecting appropriate drug-nucleic acid combinations as well as progress in the development of nanocarriers suitable for simultaneous delivery of drug-nucleic acid combinations. (C) 2013 Elsevier B.V. All rights reserved.

【 授权许可】

Free